Table 1.
Patient characteristics and demographics at baseline (N = 199).
| Patient characteristics | MONO (N = 131) |
COMBO (N = 68) |
P value |
|---|---|---|---|
| Age (years) | |||
| Median (range) | 76 (70–90) | 73 (70–86) | |
| <75 years | 51 (38.9) | 49 (72.1) | 0.638 |
| ≧75 years | 80 (61.1) | 19 (27.9) | |
| Sex | |||
| Male | 107 (81.7) | 50 (73.5) | 0.202 |
| Female | 24 (18.3) | 18 (26.5) | |
| Smoking status | |||
| Never | 13 (9.9) | 14 (20.6) | 0.049 |
| Current or former smoker | 118 (90.1) | 54 (79.4) | |
| ECOG PS | |||
| 0 | 50 (38.2) | 25 (36.8) | 0.878 |
| 1 | 81 (61.8) | 43 (63.2) | |
| Histology | |||
| Squamous cell carcinoma | 41 (31.3) | 20 (29.4) | 0.904 |
| Adenocarcinoma | 77 (58.8) | 40 (58.8) | |
| Other | 13 (9.9) | 8 (11.8) | |
| PD-L1 status | |||
| 50–89% | 75 (57.3) | 47 (69.1) | 0.125 |
| 90–100% | 56 (42.7) | 21 (30.9) | |
| Stage | |||
| IVA | 44 (33.6) | 24 (35.3) | 0.027 |
| IVB | 51 (38.9) | 36 (52.9) | |
| Recurrence | 36 (27.5) | 8 (11.8) | |
| Liver metastasis | 15 (11.5) | 9 (13.2) | 0.819 |
| Brain metastasis | 16 (12.2) | 12 (17.6) | 0.293 |
| Treatment regimen | |||
| Pembrolizumab | 131 (100) | ||
| CBDCA/nab-PTX/Pembrolizumab | 27 (39.7) | ||
| CBDCA/PEM/Pembrolizumab | 23 (33.8) | ||
| CDDP/PEM/Pembrolizumab | 6 (8.8) | ||
| CBDCA/PTX/BEV/Atezolizumab | 7 (10.3) | ||
| CBDCA/nab-PTX/Atezolizumab | 5 (7.4) | ||
ICI, immune checkpoint inhibitor; PSM, propensity score matching; ECOG PS, Eastern Cooperative Oncology Group Performance Status; PD-L1, programmed death ligand 1; TPS, tumor proportion score; CBDCA, carboplatin; CDDP, cisplatin; PEM, pemetrexed; nab-PTX, nanoparticle albumin-bound paclitaxel; PTX, paclitaxel; BEV, bevacizumab.